Skip to Content
Søg Menu
We cover

ASCO GU 2025 | Genitourinary Cancers Symposium

ASCO GU 2025

ASCO GU

  • / marie

Novel intra-vesical drug delivery system, TAR-200, to be assessed in patients with high-risk non-muscle-invasive bladder cancer

/ BestPractice Nordic
ASCOGU22Blærecancer

Abstracts fra ASCO GU 2024

ASCO GU

/ marie

Gå ikke glip af det nyeste fra Onkologi

Skriv dig på og modtag nye artikler, MEDtalks, MEDcast, faglige test og magasiner

Send mig seneste nyt fra onkologi

ASCO GU 2022

Bone mineral density in patients with castration-sensitive prostate cancer treated with abiraterone

/ Guilhem Roubaud
ASCOGU22Prostatacancer Play the Video
Kim Nguyen Chi

New potential first-line therapy for patients with mCR-prostate cancer and HRR-alterations

/ Kim Nguyen Chi
ASCOGU22Prostatacancer Play the Video
Redas Trepiakas

CYCLONE 2: Abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer

/ Redas Trepiakas
ASCOGU22Prostatacancer Play the Video
Daniel P. Petrylak

Promising neoadjuvant antitumor activity for patients with muscle-invasive bladder cancer

/ Daniel P. Petrylak
ASCOGU22Blærecancer Play the Video
Simon Crabb

Maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma

/ Simon Crabb
ASCOGU22Blærecancer Play the Video

Nyt studie med dansk deltagelse tester abemaciclib til patienter med metastatisk mCRPC

/ BestPractice Nordic
ASCOGU22Prostatacancer

Deep PSA declines with apalutamide is associated with lower risk for worsened QoL

/ BestPractice Nordic
ASCOGU22Prostatacancer
Fred Saad

Significant effect of PARP-inhibitor olaparib plus abiraterone in patients with mCRPC

/ Fred Saad
ASCOGU22Prostatacancer Play the Video

Nivolumab plus cabozantinib as first-line treatment for patients with aRCC – Final results 

/ BestPractice Nordic
ASCOGU22Nyrecancer
Hent flere
Back to top